You need to be logged in to view this video
Building a Cannabinoid Platform in Ophthalmology
Released on Tuesday, February 8, 2022•BIOTECH
Skye Bioscience (OTCQB:SKYE) is working to solve the world's leading cause of irreversible blindness by applying advanced science to uniquely unlock the therapeutic potential of cannabinoids and create important new pharmaceutical medicines. The lead program targets glaucoma, a disease with no cure and the world's leading cause of irreversible blindness. Pre-clinical data has demonstrated that SKYE's lead molecule, SBI-100, provides superior lowering of intraocular pressure, a key cause of vision loss, compared to the top commercially marketed classes of drugs that represent 80% of a nearly $7 billion market opportunity. With key value driving milestone and catalyst on the horizon SKYE is poised for significant growth.
Punit Dhillon
Skye Bioscience, Inc.,
CEO and Chair
Punit Dhillon, CEO and chair of Skye Bioscience, is a biotech executive and previous co-founder, CEO, and director of OncoSec Medical, Inc., a leading biopharmaceutical company developing cancer immunotherapies to treat solid tumors. During his tenure at OncoSec, he oversaw and completed a partnership with Merck to launch Keynote 695, a Phase 2/3 global multi-center registration clinical study of late-stage metastatic melanoma raised over $200 million. Since moving on from this role, he has worked in various management capacities and helped to raise $500M for several companies, working together to reach essential milestones.
Trending Now
Filter By Category
Filter By Keywords
Loading...